Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
10C 1 week Product disclaimer This product is supplied strictly for laboratory research use only
Supplied by BlueNexLabs , based in Canada, makes it ideal for Canadian research laboratories seeking auditsafe, RUOlabeled reagents with verified quality documentation
The SELECT cardiovascular outcomes trial (N=17,604), published in NEJM 2023 (DOI: 10.1056/NEJMoa2307563), demonstrated a 20% reduction in major adverse cardiovascular events (MACE) -- the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke -- in overweight or obese adults without diabetes
While promising, evidence is limited to preclinical data with no registered clinical trials to date, and thus human efficacy and safety remain to be established
However, no significant differences are showed between transverse times measured with 1 ms and 2 ms echo time, for the same sample
US$ 21.25
US$ 23.06
US$ 22.07
